Enoxaparin Versus Unfractionated Heparin in PCI

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Completed

Looking for future studies?

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Hemorrhage Myocardial Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Division of Cardiology Triemli Hospital Zurich

Zurich, 8063, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

PCI for stable ischemia or ACS

Exclusion criteria

Cardiogenic shock,
Pretreatment with study drugs,
Lack of informed consent

Treatment and study plan

Enoxaparin i.v.

Drug

Unfractionated heparin

Drug

Primary outcomes

Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary outcomes

major bleeding, minor bleeding, thrombocytopenia

Sponsors and collaborators

Lead sponsor

Triemli Hospital

Other

Registry information

Important dates

Study start: 2003
Study completion: 2006
First posted: Feb 26, 2007
Registry last updated: Feb 26, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed